Prognostic Factors in Gastrointestinal Stromal Tumors: Multicenter Experience of 333 Cases from Turkey

被引:8
作者
Seker, Mesut [1 ]
Sevinc, Alper [2 ]
Yildiz, Ramazan [3 ]
Cihan, Sener [4 ]
Kaplan, Mehmet Ali [5 ]
Gokdurnali, Ayse [6 ]
Dane, Faysal [7 ]
Yaman, Emel [8 ]
Karaca, Halit [9 ]
Colak, Dilsen [10 ]
Uyeturk, Ummugul [6 ]
Bilici, Ahmet [1 ]
Ozdemir, Nuriye Yildirim [4 ]
Kalender, Mehmet Emin [3 ]
Uncu, Dogan [4 ]
Salepci, Taflan [1 ]
Isikdogan, Abdurrahman [5 ]
Benekli, Mustafa [3 ]
Ozkan, Metin [9 ]
Gumus, Mahmut [1 ]
Coskun, Ugur [3 ]
Camci, Celalettin [2 ]
Oksuzoglu, Berna [6 ]
Buyukberber, Suleyman [3 ]
机构
[1] Dr Lutfi Kirdar Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey
[2] Gaziantep Univ, Dept Med Oncol, Gaziantep Oncol Hosp, Gaziantep, Turkey
[3] Gazi Univ, Dept Med Oncol, Sch Med, Ankara, Turkey
[4] Ankara Res & Training Hosp, Dept Med Oncol, Minist Hlth, Ankara, Turkey
[5] Dicle Univ, Dept Med Oncol, Diyarbakir, Turkey
[6] Dr Abdurrahman Yurtaslan Res & Educ Hosp, Dept Med Oncol, Ankara, Turkey
[7] Marmara Univ, Dept Med Oncol, Sch Med, Istanbul, Turkey
[8] Mersin State Hosp, Dept Med Oncol, Mersin, Turkey
[9] Erciyes Univ, Dept Med Oncol, Sch Med, Kayseri, Turkey
[10] Diskapi Yildirim Beyazit Training & Res Hosp, Dept Med Oncol, Minist Hlth, Ankara, Turkey
关键词
Gastrointestinal stromal tumors; Prognosis; Turkey; TERM-FOLLOW-UP; IMATINIB MESYLATE; DIFFERENTIAL-DIAGNOSIS; DOSE IMATINIB; TRIAL; MANAGEMENT; SURVIVAL;
D O I
10.5754/hge11666
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasm of the gastrointestinal tract. In an attempt to survey the approximate incidence, clinicopathological characteristics, and immunophenotypic features of GISTs in Turkey, we conducted a clinicopathological and immunohistochemical analysis of GISTs. Methodology: Three hundred and thirty-three patients with GIST from nine institutions in Turkey were retrospectively evaluated. Results: Between January 2001 and March 2011, a total of 333 patients with GISTs were included; of these, 204 (61.2%) were male and 129 (38.8%) were female. The median age was 55 years (range; 22402 years). At the median follow-up of 26 months (range; 4-166 months), the 1-, 3- and 5-year OS rates of the 333 patients were 96.9%, 85.8% and 78.5%, respectively. The 5-year DFS rate was 40%. The 5-year OS rate and median OS time for the patients with R-0 resection were significantly higher than for patients with metastatic diseases (79.7 vs. 75.7% and not reached vs. 115 months, respectively, p=0.04). Conclusion: Although our results should be confirmed by prospective studies, we believe that they contribute to the literature because the study included both resectable and metastatic or unresectable GIST patients and multicenter findings from Turkey.
引用
收藏
页码:768 / 775
页数:8
相关论文
共 27 条
[11]   Computed tomography in gastrointestinal stromal tumors [J].
Ghanem, N ;
Altehoefer, C ;
Furtwängler, A ;
Winterer, J ;
Schäfer, O ;
Springer, O ;
Kotter, E ;
Langer, M .
EUROPEAN RADIOLOGY, 2003, 13 (07) :1669-1678
[12]   PDGFRA activating mutations in gastrointestinal stromal tumors [J].
Heinrich, MC ;
Corless, CL ;
Duensing, A ;
McGreevey, L ;
Chen, CJ ;
Joseph, N ;
Singer, S ;
Griffith, DJ ;
Haley, A ;
Town, A ;
Demetri, GD ;
Fletcher, CDM ;
Fletcher, JA .
SCIENCE, 2003, 299 (5607) :708-710
[13]   A prospective study comparing endoscopy and EUS in the evaluation of GI subepithelial masses [J].
Hwang, JH ;
Saunders, MD ;
Rulyak, SJ ;
Shaw, S ;
Nictsch, H ;
Kimmey, MB .
GASTROINTESTINAL ENDOSCOPY, 2005, 62 (02) :202-208
[14]   Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis [J].
Miettinen, M ;
Lasota, J .
VIRCHOWS ARCHIV, 2001, 438 (01) :1-12
[15]   Gastrointestinal stromal tumors of the jejunum and ileum - A clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up [J].
Miettinen, M ;
Makhlouf, H ;
Sobin, LH ;
Lasota, J .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (04) :477-489
[16]   Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: A review [J].
Miettinen, M ;
El-Rifai, W ;
Sobin, LH ;
Lasota, J .
HUMAN PATHOLOGY, 2002, 33 (05) :478-483
[17]   Gastrointestinal stromal tumors of the stomach - A clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up [J].
Miettinen, M ;
Sobin, LH ;
Lasota, J .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (01) :52-68
[18]  
Miettinen M, 2006, ARCH PATHOL LAB MED, V130, P1466
[19]   Gastrointestinal stromal tumors:: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era -: A population-based study in western Sweden [J].
Nilsson, B ;
Bümming, P ;
Meis-Kindblom, JM ;
Odén, A ;
Dortok, A ;
Gustavsson, B ;
Sablinska, K ;
Kindblom, LG .
CANCER, 2005, 103 (04) :821-829
[20]   Gastrointestinal stromal tumors: From a surgical to a molecular approach [J].
Rossi, CR ;
Mocellin, S ;
Mencarelli, R ;
Foletto, M ;
Pilati, P ;
Nitti, D ;
Lise, M .
INTERNATIONAL JOURNAL OF CANCER, 2003, 107 (02) :171-176